April 2017
Dear Colleague,
This is the eighth and last edition of our newsletter titled HER2-Positive Breast Cancer Updates.
At this time, I’d like to invite you to focus on chapter 6 of our roundtable discussion video. This section focuses on pathologic complete response rate and its relationship to measuring treatment. If you haven’t watched the full video, I encourage you to do so, as I think you’ll find it to be a valuable learning experience.
I’d also like to share some articles on such important topics as the value of neoadjuvant therapy in triple-negative and HER2-positive breast cancer, how current guidelines for HER2 gene amplification testing may leave some patients at risk for misclassification and inappropriate treatment, and an insightful study that examines population-based estimates of the incidence and prognosis for patients with brain metastases at the time of diagnosis of breast cancer.
Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com at any time. I hope you have enjoyed receiving this newsletter over the past few months.
Heather Greene, MSN, FNP, AOCNP®
The West Cancer Center
Memphis, Tennessee
